Johnson & Johnson (JNJ)

JNJ on New York Consolidated

102.11USD
25 Jul 2014
Price Change (% chg)

$-0.09 (-0.09%)
Prev Close
$102.20
Open
$102.27
Day's High
$102.40
Day's Low
$101.80
Volume
3,952,062
Avg. Vol
6,298,404
52-wk High
$106.74
52-wk Low
$85.50

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.57
Market Cap (Mil.): $288,469.69
Shares Outstanding (Mil.): 2,822.60
Dividend: 0.70
Yield (%): 2.74

Financials

  JNJ Industry Sector
P/E (TTM): 18.89 35.80 36.21
EPS (TTM): 5.41 -- --
ROI: -- 18.99 18.26
ROE: -- 19.76 19.13
Search Stocks

Europe backs new leukemia drugs from J&J and Gilead

LONDON - Two new leukemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

10:29am EDT

Europe backs new leukaemia drugs from J&J and Gilead

LONDON, July 25 - Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

7:20am EDT

BRIEF-EU medicines agency backs new drugs from Novo Nordisk, J&J, Gilead

July 25 - The European Medicines Agency: * EU medicines agency says recommends Novo Nordisk diabetes

7:13am EDT

US STOCKS-Wall St dips after Yellen comments on valuations

* New York manufacturing hits highest level since April 2010

15 Jul 2014

J&J beats forecasts, helped by new hepatitis C drug

- Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

15 Jul 2014

UPDATE 3-J&J beats forecasts, helped by new hepatitis C drug

July 15 - Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

15 Jul 2014

Obama meets with CEOs of Goldman Sachs, others, on family issues

WASHINGTON - President Barack Obama met with Goldman Sachs Chief Executive Lloyd Blankfein, Johnson & Johnson chief Alex Gorsky and other business leaders on Monday to discuss ways to encourage companies to make their work places more family friendly.

23 Jun 2014

Obama meets with CEOs of Goldman Sachs, others, on family issues

WASHINGTON, June 23 - President Barack Obama met with Goldman Sachs Chief Executive Lloyd Blankfein, Johnson & Johnson chief Alex Gorsky and other business leaders on Monday to discuss ways to encourage companies to make their work places more family friendly.

23 Jun 2014

Medtronic to buy Covidien for $42.9 billion, rebase in Ireland

- U.S. medical device maker Medtronic Inc said on Sunday it had agreed to buy Covidien Plc for $42.9 billion in cash and stock and move its executive base to Ireland in the latest transaction aiming for lower corporate tax rates abroad.

16 Jun 2014

J&J links up with GSK-led group on new two-drug HIV tablet

LONDON, June 12 - Johnson & Johnson has linked up with ViiV Healthcare - a specialist HIV company majority-owned by GlaxoSmithKline - to develop a new AIDS medicine combining two drugs in a single tablet.

12 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks